New platinum compound shows promise in tumor cells

Dec 07, 2009
A diagram of cisplatin.

(PhysOrg.com) -- MIT chemists have developed a new platinum compound that is as powerful as the commonly used anticancer drug cisplatin but better able to destroy tumor cells.

The new compound, mitaplatin, combines cisplatin with another compound, dichloroacetate (DCA), which can alter the properties of selectively in . Cancer cells switch their mitochondrial properties to change the way they metabolize glucose compared to normal cells, and DCA specifically targets the altered mitochondria, leaving normal cells intact.

"This differential effect conveys on mitaplatin the ability to kill cancer cells selectively in a co-culture with normal fibroblast cells, the latter being unaffected at the doses that we apply," says Stephen Lippard, the Arthur Amos Noyes Professor of Chemistry.

The chemists designed mitaplatin so that when it enters a cell, it releases cisplatin and two units of DCA by intracellular reduction. Therefore, mitaplatin can attack nuclear DNA with cisplatin and mitochondria with DCA. DCA promotes the release of cell-death-promoting factors from the mitochondria, enhancing the cancer cell-killing abilities of cisplatin.

Lippard's laboratory has shown that in rodents, mitaplatin can be tolerated at much higher doses than cisplatin, and they have begun studies in mice transplanted with human tissues. If those results are promising, the researchers plan more studies for further demonstration of mitaplatin's ability in cancer therapy.

More information: "Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate," Shanta Dhar and Stephen Lippard. , week of Dec. 7, 2009.

Source: Massachusetts Institute of Technology (news : web)

Explore further: Why plants don't get sunburn

add to favorites email to friend print save as pdf

Related Stories

Small molecule offers big hope against cancer

Jan 16, 2007

DCA is an odourless, colourless, inexpensive, relatively non-toxic, small molecule. And researchers at the University of Alberta believe it may soon be used as an effective treatment for many forms of cancer.

Recommended for you

Why plants don't get sunburn

20 hours ago

Plants rely on sunlight to make their food, but they also need protection from its harmful rays, just like humans do. Recently, scientists discovered a group of molecules in plants that shields them from ...

Viral switches share a shape

Oct 27, 2014

A hinge in the RNA genome of the virus that causes hepatitis C works like a switch that can be flipped to prevent it from replicating in infected cells. Scientists have discovered that this shape is shared by several other ...

'Sticky' ends start synthetic collagen growth

Oct 27, 2014

Rice University researchers have delivered a scientific one-two punch with a pair of papers that detail how synthetic collagen fibers self-assemble via their sticky ends.

Cell membranes self-assemble

Oct 27, 2014

A self-driven reaction can assemble phospholipid membranes like those that enclose cells, a team of chemists at the University of California, San Diego, reports in Angewandte Chemie.

Emergent behavior lets bubbles 'sense' environment

Oct 27, 2014

Tiny, soapy bubbles can reorganize their membranes to let material flow in and out in response to the surrounding environment, according to new work carried out in an international collaboration by biomedical ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Birger
not rated yet Dec 08, 2009
The University of Alberta is progressing with tests of DCA for cancer treatment, but since it is an "orphan drug" they have to rely on donations - the pharmaceutical companies have no economic incentive to invest in research of a substance that cannot be patented.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.